Despite lower revenue, Zumiez's P/S ratio aligns with the industry, hinting at overlooked limited growth expectations. The weaker revenue outlook could lead to a share price and P/S ratio drop. A positive shift is needed to justify the current P/S ratio.
The company's CEO, Rick Brooks, stated that they are reviewing cost-saving strategies which could include closing underperforming stores and reducing labor costs. Despite the downbeat outlook, the company expects to open 10 new stores.
The three-year loss experienced by shareholders may indicate unresolved business challenges. This long-term share price weakness is generally considered a bad sign. However, some contrarian investors might research the stock in hope of a turnaround.
Ark Invest buys more Coinbase shares amid SEC crackdown Cathie Wood's Ark Invest boosted its holdings in$Coinbase (COIN.US)$amidst a crypto industry crackdown by the SEC, driving the stock to nearly five-month lows. Data from Cathie's Ark revealed that three of Wood's funds purchased over 400,000 Coinbase shares, with her main$ARK Innovation ETF (ARKK.US)$acquiring more than 300,000. This occurred as Coinbase's stock pri...
Gapping up $DocuSign (DOCU.US)$+16% (fiscal second-quarter earnings and revenue that topped Wall Street estimates and raised its forecast for fiscal-year billings.) $Zscaler (ZS.US)$+15% (the internet security platform issued a forecast better than Wall Street estimates.) $Tesla (TSLA.US)$+1.3% (The electric vehicle maker is considering building a lithium refinery for EV battery production in Texas this year, according to an applicati...
$Zumiez (ZUMZ.US)$Even after accounting for negative growth for the next 5 years, and lower margins, on my most conservative estimates this stock should be at least 2x in the coming years.
Gainers: •$Okta (OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo (STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics (TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals (AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
Zumiez Stock Forum
Zumiez Q3 Net Income USD 1.159 Million Vs. IBES Estimate USD 440 Thousand
Cathie Wood's Ark Invest boosted its holdings in $Coinbase (COIN.US)$ amidst a crypto industry crackdown by the SEC, driving the stock to nearly five-month lows. Data from Cathie's Ark revealed that three of Wood's funds purchased over 400,000 Coinbase shares, with her main $ARK Innovation ETF (ARKK.US)$ acquiring more than 300,000. This occurred as Coinbase's stock pri...
$DocuSign (DOCU.US)$ +16% (fiscal second-quarter earnings and revenue that topped Wall Street estimates and raised its forecast for fiscal-year billings.)
$Zscaler (ZS.US)$ +15% (the internet security platform issued a forecast better than Wall Street estimates.)
$Tesla (TSLA.US)$ +1.3% (The electric vehicle maker is considering building a lithium refinery for EV battery production in Texas this year, according to an applicati...
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
No comment yet